BDSX News and Press, Biodesix Inc. From 04/09/24

Studies highlight advancements in technology to detect cell-free DNA and rapid turnaround time in a real-world clinical setting Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the Americ...

2024-04-05 07:33:29 ET More on Biodesix Biodesix, Inc. (BDSX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Biodesix Read the full article on Seeking Alpha For further details see: Biodesix prices its 17.4M shares offering at $1....

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. In addition, Biodesix has entered into securities pu...

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a developm...

Eurofins Scientific S.E. (ERFSF) is expected to report for Q4 2023 Biodesix Inc. (BDSX) is expected to report $-0.1 for Q4 2023 Tapinator Inc (TAPM) is expected to report for quarter end 2023-12-31 Rapid Micro Biosystems Inc. (RPID) is expected to report $-0.31 for Q4 2023 Galapag...

Persistent, high double-digit growth in Lung Diagnostic test volume - growing 65% in FY2023 versus FY2022 - and the sixth consecutive quarter with greater than 50% year-over-year growth; Ongoing improvement in gross profit margin with achievement of 77% in fourth quarter 2023, up 11 point...

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the TD Cowen 44th Annual Health Care Conference, which will be hel...

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2023 before the open of trading on Friday, March 1. Biodesix’s management will hos...

2024-01-26 09:04:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and lo...

Capillary device supports in-office blood collection in diverse practice locations without the need for venipuncture Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of collectin...